AtaiBeckley Completes Dosing in Phase 2b Trial for VLS-01 Treatment of Depression

AtaiBeckley Inc. (NASDAQ:ATAI) has completed patient dosing in its Phase 2b Elumina clinical trial evaluating VLS-01, a DMT buccal film, for treatment-resistant depression. Topline results are expected by the end of Q4 2026. Canaccord raised ATAI's price target to $17 from $15 and maintained its Buy rating following this development.

By Laiba Immad Wed, July 15, 2026 at 12:22 PM GMT+3 2 min read · Yahoo Finance · July 15, 2026, 09:22 UTC

Tickers: $ATAI

Topics: mental health treatment phase 2 clinical trials psychedelic medicine

Read the full article at Yahoo Finance

More World news

Stellantis CEO Warns of Multi-Billion Euro Impact from Chip Shortages and Raw Material Costs Seeking Alpha · November 12, 2026, 16:44 UTC
UBS Upgrades Rivian to Buy Rating Amid R2 Potential Motley Fool · November 12, 2026, 16:45 UTC
Stifel Downgrades EVgo to Hold Amid Weakening Growth Outlook Seeking Alpha · November 12, 2026, 16:41 UTC
Rowan Digital Infrastructure Secures Over $1.5 Billion in New Financing Seeking Alpha · November 12, 2026, 16:42 UTC
CAE Reports Q2 2027 Results with Increased EPS Guidance and Strong Defense Growth Motley Fool · November 12, 2026, 16:39 UTC
Alvotech Reports Q3 2026 Financial Results Amid Manufacturing Recovery Motley Fool · November 12, 2026, 16:39 UTC
Jacobs Solutions Declares Quarterly Dividend of $0.36 Per Share Seeking Alpha · November 12, 2026, 16:39 UTC
SOLV Energy Raises Revenue Guidance Following Record Q3 Project Execution Seeking Alpha · November 12, 2026, 16:40 UTC
LiveWorld Reports Q3 Revenue of $2.98 Million and GAAP EPS of -$0.01 Seeking Alpha · November 12, 2026, 16:37 UTC
Jensen Huang Resigns as Nvidia CEO Amid Allegations of Chinese Espionage The Verge · November 12, 2026, 16:30 UTC